Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity.
about
Tuberculosis vaccines: beyond bacille Calmette-GuerinThe Zebrafish Breathes New Life into the Study of TuberculosisHost immune responses to mycobacterial antigens and their implications for the development of a vaccine to control tuberculosisPrime-boost approaches to tuberculosis vaccine developmentCD4+ T Cells Recognizing PE/PPE Antigens Directly or via Cross Reactivity Are Protective against Pulmonary Mycobacterium tuberculosis InfectionExposure to a Mycobacterial Antigen, ESAT-6, Exacerbates Granulomatous and Fibrotic Changes in a Multiwall Carbon Nanotube Model of Chronic Pulmonary DiseaseMycobacterium tuberculosis MycP1 protease plays a dual role in regulation of ESX-1 secretion and virulenceSecreted transcription factor controls Mycobacterium tuberculosis virulenceThe HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunityPreclinical evidence for implementing a prime-boost vaccine strategy for tuberculosisSimultaneous immunization against tuberculosisBoosting BCG-primed mice with chimeric DNA vaccine HG856A induces potent multifunctional T cell responses and enhanced protection against Mycobacterium tuberculosis.Immunoprophylaxis of tuberculosis: an update of emerging trends.Toward novel vaccines against tuberculosis: current hopes and obstacles.Cellular immune responses to nine Mycobacterium tuberculosis vaccine candidates following intranasal vaccination.Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen doseTransient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin.Paediatric tuberculosis.Immunization with a bivalent adenovirus-vectored tuberculosis vaccine provides markedly improved protection over its monovalent counterpart against pulmonary tuberculosisEfficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trialThe impact of mucosal infections on acquisition and progression of tuberculosis.Exosomes carrying mycobacterial antigens can protect mice against Mycobacterium tuberculosis infection.Role of 4-1BB receptor in the control played by CD8(+) T cells on IFN-gamma production by Mycobacterium tuberculosis antigen-specific CD4(+) T CellsA booster vaccine expressing a latency-associated antigen augments BCG induced immunity and confers enhanced protection against tuberculosis.Probing local innate immune responses after mucosal immunisationComparison of BCG prime-DNA booster and rBCG regimens for protection against tuberculosis.Enhanced immune response and protective effects of nano-chitosan-based DNA vaccine encoding T cell epitopes of Esat-6 and FL against Mycobacterium tuberculosis infection.Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in miceImmunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein.The M. tuberculosis phosphate-binding lipoproteins PstS1 and PstS3 induce Th1 and Th17 responses that are not associated with protection against M. tuberculosis infection.A multi-antigenic adenoviral-vectored vaccine improves BCG-induced protection of goats against pulmonary tuberculosis infection and prevents disease progression.The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infectionRecombinant adenovirus delivery of calreticulin-ESAT-6 produces an antigen-specific immune response but no protection against a Mycobacterium tuberculosis challenge.Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy.Roles of Mucosal Immunity against Mycobacterium tuberculosis InfectionNK cells influence both innate and adaptive immune responses after mucosal immunization with antigen and mucosal adjuvant.Organ distribution of transgene expression following intranasal mucosal delivery of recombinant replication-defective adenovirus gene transfer vectorAdvances in the Diagnosis, Treatment and Control of HIV Associated TuberculosisThe TB-specific CD4(+) T cell immune repertoire in both cynomolgus and rhesus macaques largely overlap with humans.CBA/J mice generate protective immunity to soluble Ag85 but fail to respond efficiently to Ag85 during natural Mycobacterium tuberculosis infection.
P2860
Q22242669-EF5512FF-0EAF-4995-BBD4-5C48830A0371Q26744620-C95EDF74-41BE-45A9-ABE3-D33D0BAFA9A1Q26863391-40AD6301-7618-4D5C-93AF-6B33BE4848EBQ27024526-A67619A5-66DB-4880-BC9C-8D849C7085FEQ27312482-24940A3B-40D5-443C-94E5-8BA66A88CFB9Q28390581-CEEE7067-95D0-4377-9390-FBBB2A525E8BQ28486671-1ACF3299-288C-4F87-88BC-2D75A05A0116Q28487057-3C49F103-4C24-49AA-ADB5-62F044E4FD73Q28727776-15C42C9B-5F0B-4A81-94D5-D54A3BF25AA3Q28730427-C0F0CACB-6115-40C6-8EE6-422700FB4A54Q28742666-AE6D3707-F915-440D-B665-2B58ECAC4236Q30376072-62E639FC-C604-4F93-8DAA-755E6D485DC8Q30385462-64E80795-C0BA-4884-A7EF-009EF065DBC2Q30484783-AD856462-C9D8-466A-9C93-660C2C8584FEQ31028998-97D51647-93BD-4EEE-B100-158F9090BEFCQ33468422-A77B8126-0107-4455-B7E6-18A0C1401922Q33503623-944972CE-C2A2-42C3-B052-5A155B835DD1Q33581724-603E1AEA-0BD6-4D95-AD70-0D580EFB7DA0Q33713700-04C8AEA0-9204-4A6E-8555-0F41A74E1BF1Q33793948-FE3E770A-17A3-4B65-9DD7-0EE6193AC85BQ33824260-6B288123-1A17-451F-A64D-DB07D84415A5Q33827831-F1054CCE-4095-4CFF-8333-9FABEED72C3EQ33900380-FE2215A3-E987-4485-9C24-791BB7C6DB90Q33999520-DFEA7CC4-1DBB-4A49-A391-DB45F9F1E94AQ34154378-9B856561-4A04-417E-9715-B1AFA1D081F6Q34290885-D8BB7829-B0AF-4ACF-A2AD-4B88203BC5FAQ34700107-2DED0BCF-7ADE-42E9-8D1A-967AE6DDB9ADQ34722855-56E656D8-5893-487D-93B6-6C2289E0043CQ34726923-85198126-C32D-4B9A-A833-3A81F95BC9CDQ34983762-465A0BFA-CD30-4923-BAA7-4133830C189DQ35054007-84499BA9-6A3A-457B-90C8-9C909F1BD5C7Q35640563-18127B6C-BAD1-4ABF-98C6-4D12F8ACF3F7Q35919921-63B832D8-2BDD-4EEC-BB96-25EA2C755BB8Q36372507-CFD27BED-CF67-4780-84F8-F6CF303F62C3Q36417953-AB9EF5A2-4980-4C0C-B99A-47C08C34456AQ36455293-7A37CF1C-AE0D-4ADF-85C1-3A740CAA61DFQ36485052-48F3A69B-5618-428D-8CFD-53AEC92A99F2Q36627619-BD07C5D1-39F5-430B-A1F7-BFE5A68DA684Q36636763-5BB1D810-B8E7-4B7C-9C00-975B4A89F0EDQ36811028-B3D3D130-B440-45BF-8ABB-44E073A7A95C
P2860
Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Mucosal administration of Ag85 ...... llus Calmette-Guerin immunity.
@en
Mucosal administration of Ag85 ...... llus Calmette-Guerin immunity.
@nl
type
label
Mucosal administration of Ag85 ...... llus Calmette-Guerin immunity.
@en
Mucosal administration of Ag85 ...... llus Calmette-Guerin immunity.
@nl
prefLabel
Mucosal administration of Ag85 ...... llus Calmette-Guerin immunity.
@en
Mucosal administration of Ag85 ...... llus Calmette-Guerin immunity.
@nl
P2093
P1476
Mucosal administration of Ag85 ...... llus Calmette-Guerin immunity.
@en
P2093
Charlotte Green Jensen
Claire Andersen
Jes Dietrich
T Mark Doherty
P304
P356
10.4049/JIMMUNOL.177.9.6353
P407
P577
2006-11-01T00:00:00Z